Ignite Creation Date:
2024-05-05 @ 10:59 PM
Last Modification Date:
2024-10-26 @ 10:26 AM
Study NCT ID:
NCT01224028
Status:
COMPLETED
Last Update Posted:
2014-08-21
First Post:
2010-10-18
Brief Title:
A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
Double-blind Randomized Placebo-controlled Clinical Trial for the Efficacy and Safety of a Calcineurin Inhibitor TacrolimusPrograf Cap in Patients With Non-nephrotic Albuminuric Normotensive IgA Nephropathy
Status:
COMPLETED
Status Verified Date:
2014-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to evaluate efficacy and safety of tacrolimus in the patients with non-nephrotic albuminuric normotensive IgA nephropathy after 16 week treatment with tacrolimus Prograf or placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None